Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Irritant occupational exposure and specific-IgE sensitisation in the EGEA cohort.

Occupational and environmental medicine·2026
Same author

Occupational Asthma Without Nonspecific Bronchial Hyperresponsiveness.

The journal of allergy and clinical immunology. In practice·2026
Same author

Allergy to Cats: Current Perspectives and Therapeutic Options.

Clinical and translational allergy·2026
Same author

Five-Grass-Pollen Sublingual Immunotherapy Drops Are Efficacious and Well Tolerated in Adults: The RHAPSODY Phase III Trial.

Allergy·2025
Same author

Occupational Asthma Due to Hair Dyes Containing Para-Amino Compounds.

American journal of industrial medicine·2025
Same author

Improvement of the therapeutic management of allergic patients in Europe - An expert think tank's position paper on allergen immunotherapy.

The World Allergy Organization journal·2025
Same journal

Impact of Therapeutic Hypothermia on Oxygen Demand and Respiratory Function in Post-Cardiac Arrest Patients: A Retrospective Cohort Study.

Respiratory medicine·2026
Same journal

The longitudinal decrease in exercise tolerance and disease progression in mild-to-moderate COPD.

Respiratory medicine·2026
Same journal

The implications of adopting the race-neutral spirometry equations in the detection of airway obstruction in Chilean children with asthma.

Respiratory medicine·2026
Same journal

Long-term outcomes of home mechanical ventilation in Duchenne Muscular Dystrophy - an observational study.

Respiratory medicine·2026
Same journal

CT-derived vascular parameters and bone mineral density in adults with cystic fibrosis.

Respiratory medicine·2026
Same journal

Effects of Integrated Inspiratory-Expiratory Muscle Training Within Hybrid Cardiac Rehabilitation Following Cardiac Surgery: A Randomized Controlled Study.

Respiratory medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 9, 2026

Development of an in vitro model system for studying the interaction of Equus caballus IgE with its high-affinity receptor FcεRI
07:31

Development of an in vitro model system for studying the interaction of Equus caballus IgE with its high-affinity receptor FcεRI

Published on: November 1, 2014

Omalizumab-induced decrease of FcξRI expression in patients with severe allergic asthma.

Pascal Chanez1, Cécile Contin-Bordes, Gilles Garcia

  • 1INSERM U 600, CNRS UMR 6212, Université de la Méditerranée, Marseille, France.

Respiratory Medicine
|August 31, 2010
PubMed
Summary
This summary is machine-generated.

Omalizumab significantly reduced immunoglobulin E high-affinity receptor (FcɛRI) on immune cells in severe asthma patients. However, this reduction did not correlate with clinical improvements, questioning its use as a predictive marker.

More Related Videos

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Related Experiment Videos

Last Updated: Jun 9, 2026

Development of an in vitro model system for studying the interaction of Equus caballus IgE with its high-affinity receptor FcεRI
07:31

Development of an in vitro model system for studying the interaction of Equus caballus IgE with its high-affinity receptor FcεRI

Published on: November 1, 2014

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Area of Science:

  • Immunology
  • Allergy and Clinical Immunology
  • Pharmacology

Background:

  • Omalizumab is known to decrease FcɛRI expression on various cell types.
  • This effect has not been previously studied in patients with uncontrolled severe persistent allergic asthma.

Purpose of the Study:

  • To investigate the effect of omalizumab on FcɛRI expression in patients with uncontrolled severe persistent allergic asthma.
  • To explore FcɛRI expression as a potential marker for treatment response in this patient population.

Main Methods:

  • A 16-week, double-blind, randomized, placebo-controlled study.
  • Patients with severe allergic asthma received either omalizumab (n=20) or placebo (n=11).
  • FcɛRI expression on basophils and plasmacytoid dendritic cells was measured by flow cytometry.

Main Results:

  • Omalizumab treatment significantly reduced FcɛRI expression on basophils (-82.6%) and plasmacytoid dendritic cells (-44.2%) compared to placebo.
  • No correlation was found between FcɛRI expression reduction and clinical response parameters.

Conclusions:

  • Long-term omalizumab treatment effectively reduces FcɛRI expression on circulating immune cells in severe asthma.
  • The lack of association with clinical outcomes suggests FcɛRI expression is not a reliable predictive marker for omalizumab response in severe asthma.